Ke Wu to Retrospective Studies
This is a "connection" page, showing publications Ke Wu has written about Retrospective Studies.
Connection Strength
0.087
-
Lin WC, Tai WC, Chang CH, Tu CH, Feng IC, Shieh MJ, Chung CS, Yen HH, Chou JW, Wong JM, Liu YH, Huang TY, Chuang CH, Tsai TJ, Chiang FF, Lu CY, Hsu WH, Yu FJ, Chao TH, Wu DC, Ho AS, Lin HH, Feng CL, Wu KL, Wong MW, Tung CC, Lin CC, Chen CC, Hu HM, Lu LS, Wang HS, Wu IC, Kuo HY, Wu JF, Yao Shih H, Ni YH, Tang SL, Chen PH, Wei SC. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflamm Bowel Dis. 2023 11 02; 29(11):1730-1740.
Score: 0.032
-
Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, Tung SY, Chung CS, Su MY, Chiu CT. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study. J Formos Med Assoc. 2022 Sep; 121(9):1689-1695.
Score: 0.028
-
Pan WH, Wu KC, Chen CY, Chu YR, Wu SC, Jou S, Lu TP, Tung YC, Hsu J, Chen WJ. First-time offenders for recreational ketamine use under a new penalty system in Taiwan: incidence, recidivism and mortality in national cohorts from 2009 to 2017. Addiction. 2021 07; 116(7):1770-1781.
Score: 0.026